A COST-EFFECTIVENESS ANALYSIS OF XELOX AND FOLFOX-4 COMBINED WITH OR WITHOUT BEVACIZUMAB FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER IN SPAIN

被引：0
|
作者：
Darba, J. [1 ]
Restovic, G. [2 ]
Ramirez de Arellano, A. [3 ]
机构：
[1] Univ Barcelona, Barcelona, Spain
[2] BCN Hlth Econ & Outcomes Res SL, Barcelona, Spain
[3] Roche Farma SA, Madrid, Spain
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)66563-1
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A467 / A467
页数：1
相关论文
共 50 条
  • [31] XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results
    J Cassidy
    S Clarke
    E Díaz-Rubio
    W Scheithauer
    A Figer
    R Wong
    S Koski
    K Rittweger
    F Gilberg
    L Saltz
    British Journal of Cancer, 2011, 105 : 58 - 64
  • [32] FOLFOX-4 versus FOLFIRI in the treatment of metastatic colorectal cancer - a prospective randomised study
    Badulescu, F.
    Badulescu, A.
    Schenker, M.
    Ionescu, M.
    Ninulescu, C.
    Crisan, A.
    Dinescu, S.
    EJC SUPPLEMENTS, 2009, 7 (02): : 349 - 349
  • [33] Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials
    Shiroiwa, T.
    Fukuda, T.
    Tsutani, K.
    BRITISH JOURNAL OF CANCER, 2009, 101 (01) : 12 - 18
  • [34] Effectiveness and Cost Effectiveness of Bevacizumab in Metastatic Colorectal Cancer
    Messori, Andrea
    De Rosa, Mauro
    Fadda, Valeria
    Pani, Luca
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (32) : 3838 - +
  • [35] Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials
    T Shiroiwa
    T Fukuda
    K Tsutani
    British Journal of Cancer, 2009, 101 : 12 - 18
  • [36] XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results
    Cassidy, J.
    Clarke, S.
    Diaz-Rubio, E.
    Scheithauer, W.
    Figer, A.
    Wong, R.
    Koski, S.
    Rittweger, K.
    Gilberg, F.
    Saltz, L.
    BRITISH JOURNAL OF CANCER, 2011, 105 (01) : 58 - 64
  • [37] The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales
    Tappenden, P.
    Jones, R.
    Paisley, S.
    Carroll, C.
    EUROPEAN JOURNAL OF CANCER, 2007, 43 (17) : 2487 - 2494
  • [38] Cost comparison of XELOX vs. FOLFOX4 ± bevacizumab as first-line treatment in patients with metastatic colorectal cancer (MCRC):: US findings
    Garrison, L.
    Cassidy, J.
    Saleh, M.
    Lee, F.
    Mena, R.
    Fuloria, J.
    Chang, V
    Ervin, R.
    Stella, P.
    Saltz, L.
    ANNALS OF ONCOLOGY, 2007, 18 : VII74 - VII74
  • [39] Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer
    Goldstein, Daniel A.
    Ahmad, Bilal B.
    Chen, Qiushi
    Ayer, Turgay
    Howard, David H.
    Lipscomb, Joseph
    El-Rayes, Bassel F.
    Flowers, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [40] Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer
    Goldstein, Daniel A.
    Ahmad, Bilal B.
    Chen, Qiushi
    Ayer, Turgay
    Howard, David H.
    Lipscomb, Joseph
    El-Rayes, Bassel F.
    Flowers, Christopher R.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (32) : 3727 - +
12345